Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. (Q53317535)
Jump to navigation
Jump to search
scientific article published in March 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. |
scientific article published in March 2011 |
Statements
Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. (English)
Paul S Aisen
1 reference
Anthony C Gamst
1 March 2011
7
2
245-6; author reply 247-9